Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Clements

Showing results (41-50 of 130) with videos related to

Pageof 13
Sort By:
Cancer Chemotherapy and Pharmacology|January 1, 1997
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cellsC B Jones, M K Clements, S Wasi, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
Antiangiogenic potential of camptothecin and topotecanM K Clements, C B Jones, M Cumming, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1991
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesS Ostrand-Rosenberg, C Roby, V K Clements, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrestC B Jones, M K Clements, S Wasi, et al.
International Journal of Oncology|October 13, 2000
UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cellsC B Jones, M K Clements, A Redkar, et al.
Plos Genetics|December 20, 2023
Constitutively active CaMKII Drives B lineage acute lymphoblastic leukemia/lymphoma in tp53 mutant zebrafishSarah C Rothschild, Guanhua Lai, Robert M Tombes, et al.
Journal of Immunogenetics|August 1, 1989
Transfection of major histocompatibility complex class I and class II genes causes tumour rejectionS Ostrand-Rosenberg, V K Clements, A Thakur, et al.
Cancer Research|May 8, 2007
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cellsPratima Sinha, Virginia K Clements, Amy M Fulton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1992
Invariant chain alters the malignant phenotype of MHC class II+ tumor cellsV K Clements, S Baskar, T D Armstrong, et al.
Seminars in Cancer Biology|February 9, 2012
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppressionSuzanne Ostrand-Rosenberg, Pratima Sinha, Daniel W Beury, et al.
Pageof 13

Showing results (41-50 of 130) with videos related to

Sort By:
Pageof 13
Cancer Chemotherapy and Pharmacology|January 1, 1997
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cellsC B Jones, M K Clements, S Wasi, et al.
Cancer Chemotherapy and Pharmacology|September 29, 1999
Antiangiogenic potential of camptothecin and topotecanM K Clements, C B Jones, M Cumming, et al.
International Journal of Cancer. Supplement = Journal International Du Cancer. Supplement|January 1, 1991
Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesS Ostrand-Rosenberg, C Roby, V K Clements, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrestC B Jones, M K Clements, S Wasi, et al.
International Journal of Oncology|October 13, 2000
UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cellsC B Jones, M K Clements, A Redkar, et al.
Plos Genetics|December 20, 2023
Constitutively active CaMKII Drives B lineage acute lymphoblastic leukemia/lymphoma in tp53 mutant zebrafishSarah C Rothschild, Guanhua Lai, Robert M Tombes, et al.
Journal of Immunogenetics|August 1, 1989
Transfection of major histocompatibility complex class I and class II genes causes tumour rejectionS Ostrand-Rosenberg, V K Clements, A Thakur, et al.
Cancer Research|May 8, 2007
Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cellsPratima Sinha, Virginia K Clements, Amy M Fulton, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 1, 1992
Invariant chain alters the malignant phenotype of MHC class II+ tumor cellsV K Clements, S Baskar, T D Armstrong, et al.
Seminars in Cancer Biology|February 9, 2012
Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppressionSuzanne Ostrand-Rosenberg, Pratima Sinha, Daniel W Beury, et al.
Pageof 13